External validation of the systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in cancer patients - Takeaways - MDSpire

External validation of the systematic coronary risk evaluation 2 (SCORE2) and SCORE2-older persons in cancer patients

  • By

  • Mari Nordbø Gynnild

  • Joris Holtrop

  • Steven H J Hageman

  • Victoria Vinje

  • Jannick A N Dorresteijn

  • Frank L J Visseren

  • Espen Holte

  • Håvard Dalen

  • Torgeir Wethal

  • Torbjørn Omland

  • June 23, 2025

  • 0 min

Share

  • 1

    The study aimed to validate and recalibrate SCORE2 and SCORE2-OP models for predicting cardiovascular risk in cancer patients.

  • 2

    A total of 1622 cancer patients were included, with a median follow-up of 8.8 years, during which 252 cardiovascular events occurred.

  • 3

    SCORE2 initially underestimated cardiovascular risk in cancer patients but showed improved accuracy after recalibration.

  • 4

    C-statistics for SCORE2 improved from 0.693 to 0.730 after excluding early deaths, indicating better predictive performance.

  • 5

    Further validation of SCORE2 and SCORE2-OP in specific cancer subgroups is necessary to enhance risk stratification in this population.

Original Source(s)

Related Content